PMGC Holdings subsidiary NorthStrive amends YuvaBio deal for three-phase expansion
PMGC Holdings, via subsidiary NorthStrive Biosciences, entered a First Amendment with Yuva Biosciences on Aug 27, 2026 to launch a three-phase Expansion Program advancing up to four AI-discovered compounds toward lead nomination.
PMGC Holdings, through subsidiary NorthStrive Biosciences, entered into a First Amendment to its Development and License Agreement with Yuva Biosciences on Aug 27, 2026.
The amendment launches a three-phase Expansion Program to advance up to four AI-discovered compounds toward lead nomination, and…